Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) received notification from the European Patent Office (EPO) of its intention to grant the company’s patent application related to a method of using Biomoda’s proprietary porphyrin-based compound to detect cancer and pre-cancerous cells in body fluid and tissue samples.
With the EPO patent, we may be able to launch CyPath® as a screening tool in Europe and start collecting revenue from sales prior to FDA approval in the U.S.”
News 
Market Data 
Discover 
